Evidence map›Paper›PMID 26469083›Full record

Trial reportScientific reports2015

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.

Chen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, Chia-Yen Dai, Jee-Fu Huang, Jou-Wei Lin, Cheng-Chao Liang, Sheng-Shun Yang, Chih-Lin Lin, Tung-Hung Su and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chen-Hua LiuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chung-Feng HuangInstitute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chun-Jen LiuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Yen DaiInstitute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jee-Fu HuangInstitute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jou-Wei LinDepartment of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan.
Cheng-Chao LiangDepartment of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan.
Sheng-Shun YangDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Chih-Lin LinDepartment of Gastroenterology, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan.
Tung-Hung SuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hung-Chih YangHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Pei-Jer ChenDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Ding-Shinn ChenDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wan-Long ChuangInstitute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jia-Horng KaoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Ming-Lung YuInstitute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV. Treatment-naïve HCV-2 patients with rapid virologic response (RVR) received Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000 or 1,200 mg/day; cut-off body weight: 75 kg) for 6 weeks, and then randomly received Peg-IFN alfa-2a 180 μg/week plus weight-based (1,000 or 1,200 mg/day; n = 247) or flat-dose (800 mg/day; n = 246) RBV for additional 10 weeks. The primary endpoint was SVR24. Patients receiving weight-based and flat-dose RBV therapies had comparable SVR24 rates (93.5% versus 91.9%, P = 0.49). The risk differences (RDs) of SVR24 receiving weight-based and flat-dose RBV arms were 7.1% [95% CI: 0.7% to 13.6%] in males, and -5.8% [95% CI: -12.1% to 0.5%] in females (interaction P = 0.01). The SVR24 rate was higher in males receiving ≥13 mg/kg/day than those receiving <13 mg/kg/day (96.3% versus 85.1%, P = 0.001). In conclusion, Peg-IFN alfa-2a plus weight-based or flat-dose RBV for 16 weeks provides comparable SVR24 rates in treatment-naïve HCV-2 rapid responders. However, males should receive weight-based RBV to achieve a high SVR24 rate.

Indexed as

AdultAgedAntiviral AgentsBody WeightDose-Response Relationship, DrugFemaleGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRibavirinAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, Viral

Identifiers

PMID26469083
PMCPMC4606559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.